Microbiome therapy biotech Finch Therapeutics Group prices upsized IPO at $17 high end

Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, raised $128 million by offering 7.5 million shares at $17, the high end of the range of $15 to $17. The company offered 1.3 million more shares than anticipated.

Finch is a microbiome therapeutRead More